Susan L. Kelley

Medicine · Health Sciences

20h-index4.5kcitations40works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(8), Protein Degradation and Inhibitors(7), HIV/AIDS drug development and treatment(6), Cancer Treatment and Pharmacology(6), Drug Transport and Resistance Mechanisms(3)

Publications40 total

Ephedra monosperma (Ephedraceae), Another Gymnosperm of Noteworthy Size
Harvard Papers in Botany·2022
Mitochondria-targeted doxorubicin: A new therapeutic strategy against drug-resistant osteosarcoma
European Journal of Cancer·2016
bortezomib with refractory multiple myeloma who have received lenalidomide and Phase 1 study of pomalidomide MTD, safety, and efficacy in patients
2013
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
Blood·2012· 161 citedOpen Access
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial
Blood·2011· 89 citedOpen Access
The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics.
Blood·2010· 2 cited
Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial
Blood·2010· 16 cited
Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial
Blood·2010· 1 cited
A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or In Combination with Low-Dose Dexamethasone In Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib
Blood·2010· 7 cited
Abstract B58: Decreasing the time to activate clinical trials: Initial data from the Multiple Myeloma Research Consortium (MMRC) model
Molecular Cancer Therapeutics·2009
Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial.
Blood·2009· 18 cited
A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib.
Blood·2009· 39 cited
Flora of China Flora of China. Text, Volume 22: Poaceae. 2006. Zhengyi Wu, Peter H. Raven (co-chairs of the editorial committee) . 16 Donghuangchenggen North Street, Beijing 100717, P. R. China, and Missouri Botanical Garden Press. 433 Shaw Blvd., St. Louis, MO 63110–2291, U.S.A. xii +. 733 pp. (hardcover) US $140.00. Science Press. ISBN: 1-930723-50-4.
Harvard Papers in Botany·2008
Flora of China Illustrations Flora of China Illustrations. Volume 22: Poaceae. 2007. Zhengyi Wu (co-chairs of the editorial committee), Peter H. Raven (co-chairs of the editorial committee) . 16 Donghuangchenggen North Street, Beijing 100717, P. R. China, and Missouri Botanical Garden Press. 433 Shaw Blvd., St. Louis, MO 63110-2291, U.S.A. 937 pp. (hardcover) US$140.00. Science Press. ISBN: 978-1-930723-61-0.
Harvard Papers in Botany·2008
Erratum: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Nature Reviews Drug Discovery·2007· 13 citedOpen Access
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Nature Reviews Drug Discovery·2006· 1.8k citedOpen Access
Blockade of T Lymphocyte Costimulation with Cytotoxic T Lymphocyte–Associated Antigen 4–Immunoglobulin (Ctla4ig) Reverses the Cellular Pathology of Psoriatic Plaques, Including the Activation of Keratinocytes, Dendritic Cells, and Endothelial Cells
The Journal of Experimental Medicine·2000· 319 citedOpen Access
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
Journal of Clinical Investigation·1999· 598 citedOpen Access
CTLA4lg (BMS-188667)-mediated blockade of T cell costimulation in patients with psoriasis vulgaris
Journal of Investigative Dermatology·1997
15-deoxyspergualin: Immunotherapy in solid organ and cellular transplantation
Transplantation Reviews·1996· 23 cited
page 1 of 2Next →

Frequent Co-authors

Kenneth C. Anderson(8), Paul G. Richardson(7), Sandra Wear(6), Marcel Rozencweig(6), Jacob P. Laubach(5), Robert Schlossman(5), Andrzej Jakubowiak(5), Sagar Lonial(5), Colleen K Harvey(5), Renzo Canetta(5), David S. Siegel(4), Rachid Baz(4), Nikhil C. Munshi(4), Daniel M. Sullivan(4), Deborah Doss(4), Laura McBride(4), Gail Larkins(4), Christian Jacques(4), Kent A. Griffith(4), Donna Reece(4)